Our clinical trials

Pre-operative window-of-opportunity study of Debio 1143 with or without cisplatin in patients with resectable squamous cell carcinoma of the head and neck.

RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 2 STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH CETUXIMAB PLUS PLATINUM-BASED THERAPY IN FIRST LINE SETTING IN SUBJECTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK.

A Safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN).

A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or second line therapy in patients with advanced triple-negative breast cancer.